VTVT
vTv Therapeutics Inc.
NASDAQ · Healthcare · Biotechnology · US
$24.28
+3.10%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$23.70
From 52W high−43.16%
Volume20376.00
Market cap$96.00M
P/E (TTM)—
P/S (TTM)2.6x
Div yield—
Key dataNov 4, 2026
Open
$23.70
From 52W high
−43.16%
Volume
20376.00
Market cap
$96.00M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−1.5x
P/E (TTM)
—
RSI (14)
31.3
MomentumView details →
1D Return
+3.10%
YTD Return
−39.89%
SummaryUpdated Jun 1, 2026
vTv Therapeutics Inc. (NASDAQ:VTVT) is a clinical-stage biopharmaceutical company founded in 2015 and headquartered in High Point, North Carolina. The company operates as a subsidiary of MacAndrews & Forbes Incorporated and focuses on developing orally administered treatments primarily for diabetes and other metabolic disorders. Since its initial public offering in July 2015, vTv has been advancing a pipeline of small molecule therapeutics through various stages of clinical development, with particular emphasis on innovative approaches to treating type 1 diabetes and inflammatory conditions.
Similar companies
Latest newsMore news →
vTv Therapeutics announced that the first participant was randomized in its Phase 2a Hybrid CATT1 pilot study evaluating cadisegliatin in people with type 1 diabetes who use hybrid closed-loop insulin delivery systems.8d agoThe FDA granted orphan drug designation to vTv Therapeutics Inc.’ HPPD for sickle cell disease.28d agovTv Therapeutics completed enrollment in its Phase 3 CATT1 study of Cadisegliatin in Type 1 Diabetes, with topline results expected in mid-2027.30d ago